Genemedi produces core diagnostic ingredients for test of Infectious disease (neurological diseases ) and related syndrome. GeneMedi offers paired diagnostics grade Enterovirus 71 (VP1) antibodies (monoclonal antibody, mab) and antigens for Infectious disease (neurological diseases ) rapid test kit of Enterovirus 71 (VP1) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Infectious disease (neurological diseases ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.Enterovirus 71 (EV71), the newest member of Enterovirudae, is notable for its etiological role in epidemics of severe neurological diseases in children. It appears to be emerging as an important virulent neurotropic enterovirus in the upcoming era of poliomyelitis eradication. The illness usually peaks in June or July. EV71 infection may be asymptomatic or may cause diarrhea and rashes. EV71 one of the major causative agents for hand, foot and mouth disease (HFMD), is sometimes associated with severe central nervous system diseases. Direct detection of virus is the mainstay of diagnosis. EV71 can be isolated from throat and stool specimens, as well as from skin vesicle fluid. PCR testing provides generally greater sensitivity than culture for throat and stool specimens, and viral RNA has also been detected in vesicular fluid, blood and urine. EV71 specifc serological assays, including tests specific for IgM antibody, have also been developed to assist for early and easier diagnosis of the disease
Product Details
Product Description
Cat No. of Pruducts
Product Name
Target
Alias of Target/Biomarker
Expression platform
Isotypes
Bioactivity validation
Tag
Products description
Reconized/Reactive Species
Purity
Application
Formulation
Storage
Cat No. of Pruducts
Product Name
Target
Alias of Target/Biomarker
Expression platform
Isotypes
Bioactivity validation
Tag
Products description
Reconized/Reactive Species
Purity
Application
Formulation
Storage
Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1
Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.